MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

被引：0
|
作者：
Mamdani, H. [1 ]
Kim, S. [1 ]
Gentzler, R. [2 ]
Furqan, M. [3 ]
Shields, M. D. [4 ]
Jalal, S. I. [4 ]
机构：
[1] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[2] Univ Virginia, Charlottesville, VA USA
[3] Univ Iowa, Iowa City, IA USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Small cell lung cancer; Monalizumab; Extensive stage;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13A.03
引用
收藏
页码：S207 / S207
页数：1
相关论文
共 50 条
  • [1] A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study
    Mamdani, Hirva
    Kim, Seongho
    Gentzler, Ryan D.
    Shields, Misty Dawn
    Furqan, Muhammad
    Pizana, Kristen
    Abid, Qura
    Jalal, Shadia Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
    Reinmuth, N.
    DeMarinis, F.
    Leighl, N.
    Sadow, S.
    Davey, K.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
  • [3] CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
    Paz-Ares, L.
    Jiang, H.
    Huang, Y.
    Dennis, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2398
  • [4] ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Cang, S.
    Cao, L.
    Chen, E.
    Dong, X.
    Fan, Y.
    Gao, B.
    Guo, Q.
    Huang, D.
    Li, S.
    Liu, A.
    Lv, D.
    Pan, Y.
    Tang, K.
    Yao, W.
    Ye, F.
    Yu, Y.
    Zang, A.
    Gao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S727 - S728
  • [5] Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage- SCLC: Results From the Phase 3 MERU Study
    Johnson, Melissa L.
    Zvirbule, Zanete
    Laktionov, Konstantin
    Helland, Aslaug
    Cho, Byoung Chul
    Gutierrez, Vanesa
    Colinet, Benoit
    Lena, Herve
    Wolf, Martin
    Gottfried, Maya
    Okamoto, Isamu
    van der Leest, Cor
    Rich, Patricia
    Hung, Jen-Yu
    Appenzeller, Christina
    Sun, Zhaowen
    Maag, David
    Luo, Yan
    Nickner, Caroline
    Vajikova, Alena
    Komarnitsky, Philip
    Bar, Jair
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1570 - 1581
  • [6] A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Conkling, P. R.
    Reynolds, C.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
    Jotte, R. M.
    Reynolds, C.
    Conkling, P.
    Jungnelius, U.
    Oliver, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
  • [8] A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Reynolds, C. H.
    Conkling, P.
    Oliver, J. W.
    Allen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer
    Liu, Chang
    Liao, Jiatao
    Wu, Xianghua
    Zhao, Xinmin
    Sun, Si
    Wang, Huijie
    Hu, Zhihuang
    Zhang, Yao
    Yu, Hui
    Wang, Jialei
    THORACIC CANCER, 2022, 13 (10) : 1463 - 1470
  • [10] Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
    Reinmuth, N.
    Goldman, J. W.
    Chen, Y.
    Hotta, K.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Garassino, M. C.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Losonczy, G.
    Conev, N. V.
    Mann, H.
    Chugh, P.
    Dalvi, T. B.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1245 - S1246
12345